Keen Eye and Ultivue Announce Collaborative Agreement to Propel Multiplex and Spatial Analysis in Clinical Research
Retrieved on:
Tuesday, March 29, 2022
Technology, Biotechnology, Health, Pharmaceutical, Oncology, Other Technology, Research, Medical Devices, Software, Managed Care, Hospitals, Science, Clinical Trials, Cardiology, Biomarker, MIF, Eye, Patient, Cros, Tumor microenvironment, Research, Pathology, Noise, Precision medicine, CEO, Marie Cassidy, Industry, Technology, Spatial analysis, Doctor of Philosophy, Deep learning, CRO, Solution, AI, Partnership, Medical imaging, Fine chemical, KEEN EYE, ULTIVUE
Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.
Key Points:
- Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.
- This technology combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.
- Keen Eye is an AI Platform company dedicated to deliver accurate, standardized, and undiscovered tissue insights in research and clinical development using Deep Learning histopathology digital image analysis.
- Keen Eye is building decision-support and GCLP-compliant image analysis solutions relying on Deep Learning technology through web-based platforms.